Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | GAA | P10253 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | NAMPT | P43490 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840873 | 0.88 | TSHR (0.74) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL2840870 | 0.88 | TSHR (0.74) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL9843022 | 0.87 | GAA (0.76) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL5947516 | 0.87 | TSHR (0.77) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL6689489 | 0.87 | TSHR (0.72) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL6691604 | 0.87 | TSHR (0.72) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL6690396 | 0.87 | TSHR (0.72) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL491660 | 0.87 | TSHR (0.72) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL21639596 | 0.87 | TSHR (0.77) | TSHRRAB9AGAAKMT2AALDH1A1 | |
| SCHEMBL7141724 | 0.87 | TSHR (0.72) | TSHRRAB9AGAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905306-B2 | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus | SOUTHERN RESEARCH INSTITUTE (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE | 2023-06-22 | — | — | US | disclosed |
| US-20140228579-A1 | METHOD FOR THE CATALYTIC REDUCTION OF ACID CHLORIDES AND IMIDOYL CHLORIDES | Brock Unviersity (CA) | 2014-08-14 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| EP-0232224-B1 | PIPERIDINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1992-11-25 | — | — | EP | disclosed |
| EP-0232224-A2 | Piperidine compounds | CIBA-GEIGY AG (CH) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SARS1, ACE2, ACE | TSHR 3327/4885RAB9A 974/4885GAA 2044/4885 |
| US-11905306-B2 | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus | SARS1, ACE2, TMPRSS2 | TSHR 4253/4885RAB9A 2320/4885GAA 1437/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | TSHR 3829/4885RAB9A 2332/4885GAA 3489/4885 |
| US-20140228579-A1 | METHOD FOR THE CATALYTIC REDUCTION OF ACID CHLORIDES AND IMIDOYL CHLORIDES | CA6, RUVBL2, HACL2 | TSHR 3534/4885RAB9A 854/4885GAA 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.